What BMI do you need for Wegovy under Wellmark?

For weight loss on Employer / Commercial Insurance plans, Wellmark requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.

How long does a Wegovy approval last with Wellmark?

Initial approvals last 6 months, and renewals are granted in 12-month periods.

What does Wellmark require to renew Wegovy?

At least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose. For pediatrics (12-17): at least 5% reduction in BMI from baseline OR maintained initial 5% BMI reduction after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal.

What if my plan excludes weight loss medications?

Wellmark has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.

How current is this information?

This page reflects Wellmark's written policy as of May 19, 2026, last verified against the source document on June 3, 2026.

Wellmark

Does Wellmark cover Wegovy?

Quick answer · Weight Loss

Wellmark covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

Employer / Commercial Insurance: Depends on your plan's benefit. Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management; drugs for weight loss management are a standard exclusion for most benefit plans

Last verified June 3, 2026. Policy effective May 19, 2026. Source: Drugs-for-weight-loss-management.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN and dyslipidemia)
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Adult (18+) - Continuation/Already on therapy

All of:

Patient is 18 years of age or older
Patient has completed at least 3 months of therapy with Wegovy at a stable maintenance dose
Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Adult (18+) - New to therapy with BMI >= 30

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 30 kg/m2
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Adult (18+) - New to therapy with BMI >= 27 and comorbidity (non-CVD)

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 27 kg/m2
Patient has at least one weight-related comorbid condition (e.g., hypertension or dyslipidemia)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Pediatric (12-17) - Continuation/Already on therapy

All of:

Member is 12 to 17 years of age
Member has completed at least 3 months of therapy with Wegovy at a stable maintenance dose
Member has at least 5% reduction in BMI from baseline OR has continued to maintain their initial 5% reduction in BMI from baseline (documentation required)
Member is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Member will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Pediatric (12-17) - New to therapy

All of:

Member is 12 to 17 years of age
Member has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Member has an initial BMI at the 95th percentile or greater standardized for age and sex
Member is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Member will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

Chart notes or medical record documentation of Body Mass Index (BMI)
Chart notes or medical record documentation of weight-related comorbid condition, if applicable
Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for adults on continuation)
Documentation of at least 5% BMI reduction from baseline or maintained 5% BMI reduction (for pediatrics on continuation)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose. For pediatrics (12-17): at least 5% reduction in BMI from baseline OR maintained initial 5% BMI reduction after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1 approved for T2DM)
Combination use with another targeted weight loss agent
Plans without specific benefit language allowing weight loss drug coverage

Policy note: Document covers Wegovy (semaglutide injection), Wegovy HD (semaglutide injection), and Wegovy (semaglutide tablet) under a single section V for adults, and section VI for pediatrics. The weight loss criteria and approval durations are the same across all three formulations for the adult indication. Wegovy HD and Wegovy tablet do not have a listed pediatric indication in this policy. Members receiving medication via samples or manufacturer patient assistance programs must meet initial approval criteria. Approvals may be subject to dosing limits per FDA labeling.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Wegovy for Heart Disease Risk Reduction

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

Age 18 and older
BMI of 27 or higher
6 months of a documented diet and exercise program
Established cardiovascular disease (MI, stroke, and PAD)
On guideline-directed medical therapy (antiplatelet, lipid-lowering, and antihypertensive)
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Continuation/Already on therapy

All of:

Patient is 18 years of age or older
Patient has completed at least 3 months of therapy with Wegovy at a stable maintenance dose
Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request

CV Risk Reduction - New to therapy

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 27 kg/m2
Patient has established cardiovascular disease defined by previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease (intermittent claudication with ankle-brachial index <0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic cardiovascular disease) — documentation required
Patient is receiving and will continue standard of care treatment of cardiovascular disease including a drug from each of: antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), antihypertensive (e.g., beta-blocker, ACE inhibitors or ARBs) unless inadequate response, intolerance, documented contraindication, or medically justifiable reason to preclude use of all medications in any/all classes — documentation required
Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent

Documentation to bring

Chart notes or medical record documentation of Body Mass Index (BMI)
Chart notes, medical record documentation, or claims history supporting established cardiovascular disease (i.e., previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease)
Documentation of current standard of care treatment of cardiovascular disease including antiplatelet, lipid-lowering, and antihypertensive therapy (or clinical reason any class is not appropriate)
Documentation confirming no diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Diagnosis of diabetes mellitus within 180 days prior to the request
Diagnosis of pancreatitis within 180 days prior to the request
Combination use with another targeted weight loss agent
Plans without specific benefit language allowing weight loss drug coverage

Policy note: GDMT classes required are antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), and antihypertensive (e.g., beta-blocker, ACE inhibitors, or ARBs). Exceptions allowed for inadequate response, intolerance, documented contraindication, or medically justifiable reason. The 180-day diabetes/pancreatitis exclusion window applies to the initial approval pathway; the continuation pathway also requires 5% weight loss maintained at 3 months on stable maintenance dose. Covers Wegovy injection, Wegovy HD injection, and Wegovy tablet. Approval duration stated as 6 months for initial for 'weight loss and cardiovascular risk reduction' combined.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Wegovy for Liver Disease (MASH)

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

What you need to qualify

Age 18 and older
6 months of a documented diet and exercise program
Prescribed by or in consultation with a specialist
Confirmed MASH diagnosis by liver_biopsy, FAST (FibroScan-AST), MAST (MRI-PDFF + MRE + AST), and MEFIB (MRE + FIB-4), fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH Initial Approval

All of:

Member has a diagnosis of MASH with moderate to advanced liver fibrosis consistent with stages F2 to F3, confirmed by liver biopsy, FAST (FibroScan-AST), MAST (MRI-PDFF + MRE + AST), or MEFIB (MRE + FIB-4)
Requested medication is prescribed by or in consultation with a gastroenterologist, hepatologist, cardiometabolic specialist, or primary care physician in consultation with any of the listed specialists
Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Requested medication will be used in conjunction with healthy lifestyle modifications (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)

MASH Continuation

All of:

Member is requesting medication for continuation of therapy for MASH
Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP)
Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Requested medication will be used in conjunction with healthy lifestyle modifications

Documentation to bring

Chart notes or medical records documenting clinical findings supporting the diagnosis of MASH
Documentation of liver fibrosis staging F2-F3 confirmed by liver biopsy, FAST score, MAST score, or MEFIB score
Documentation that medication is prescribed by or in consultation with a gastroenterologist, hepatologist, cardiometabolic specialist, or PCP in consultation with listed specialists
Documentation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Documentation of positive clinical response for continuation (e.g., reduction in ALT, reduction of liver fat by MRI-PDFF or FibroScan CAP)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP). No re-verification of specialist prescribing or fibrosis confirmation methods required at continuation.

Not covered when

Cirrhosis
Hepatic decompensation
Hepatocellular carcinoma
Plans without specific benefit language allowing weight loss drug coverage

Policy note: MASH indication applies only to Wegovy (semaglutide injection), not Wegovy HD or Wegovy tablet (which are not listed under section VII). Fibrosis confirmation methods accepted: liver biopsy, FAST (FibroScan-AST), MAST (derived from MRI-PDFF + MRE + AST), and MEFIB (MRE combined with FIB-4 index). No lookback periods specified for confirmation tests. The T2DM exclusion that applies to weight_loss and cv_risk_reduction indications does NOT apply to MASH. Quantity limit applies to injection formulation only; semaglutide tablet quantity limit is 30 tabs/30 days.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Why Wegovy requests get denied by Wellmark

Based on what this policy asks for. Fix these before the first submission.

Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
Qualifying weight-related condition not documented with its own diagnosis code.
No documented diet and exercise program.
Prescriber isn't the specialist the plan requires.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Wellmark has separate Wegovy policies that don't depend on the weight loss benefit:

Heart Disease Risk Reduction — covered on Employer / Commercial Insurance.
Liver Disease (MASH) — covered on Employer / Commercial Insurance.

Wegovy is also sold directly by Novo Nordisk without insurance through NovoCare.

Frequently asked questions

Does Wellmark cover Wegovy?: Wellmark covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Wegovy under Wellmark?: For weight loss on Employer / Commercial Insurance plans, Wellmark requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Wegovy approval last with Wellmark?: Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does Wellmark require to renew Wegovy?: At least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose. For pediatrics (12-17): at least 5% reduction in BMI from baseline OR maintained initial 5% BMI reduction after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal.
What if my plan excludes weight loss medications?: Wellmark has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.
How current is this information?: This page reflects Wellmark's written policy as of May 19, 2026, last verified against the source document on June 3, 2026.

Other medications under Wellmark

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Wellmark's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.